𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Another look at MAO-B inhibitors in early Parkinson's disease

Book ID
120855327
Publisher
Adis International Limited (now part of Wolters Kluwer Health)
Year
2004
Weight
139 KB
Volume
&NA;
Category
Article
ISSN
1173-8324

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

MAO-B inhibitors for the treatment of Pa
MAO-B inhibitors for the treatment of Parkinson's disease
πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 88 KB

## INTRODUCTION BACKGROUND Early attempts to enhance dopaminergic neurotransmission through inhibition of one of dopamine's major metabolizing enzyme -monoamine oxidase (MAO) -were made soon after the discovery of the striatal dopaminergic deficit and the efficacy of L-dopa. 1 However, side-effect

Effects of tyramine administration in Pa
Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline
✍ J. Antonelle deMarcaida; Steven R. Schwid; William B. White; Karen Blindauer; St πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 76 KB

## Abstract Rasagiline is a novel, potent, and selective MAO‐B inhibitor shown to be effective for Parkinson's disease. Traditional nonselective MAO inhibitors have been associated with dietary tyramine interactions that can induce hypertensive reactions. To test safety, tyramine challenges (50–75